Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

H.J. Stewart, A P Forrest, D Everington, C C McDonald, J A Dewar, R A Hawkins, Robin J Prescott, W D George

Research output: Contribution to journalArticlepeer-review

Abstract

In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064).
Original languageEnglish
Pages (from-to)297-9
Number of pages3
JournalBritish Journal of Cancer
Volume74
Issue number2
Publication statusPublished - 1996

Keywords

  • breast cancer
  • long-term tamoxifen
  • randomised trial

Fingerprint

Dive into the research topics of 'Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group'. Together they form a unique fingerprint.

Cite this